Sander van Deventer is currently a General Partner at Forbion Capital Partners, Professor of Translational Gastroenterology Leiden University Medical Center and is the interim CEO of Amsterdam Molecular Therapeutics. He received his medical degree and doctorate of philosophy from the University of Amsterdam on the biological activities of bacterial lipopolysaccharides in humans. He worked in the Laboratory for Medical Biochemistry, Rockefeller University, New York. In 1995 he became director of the laboratory for Experimental Internal Medicine at the Academic Medical Center in Amsterdam, and continued to work on therapeutic signal transduction inhibition, gene therapy, and (genetically engineered) probiotics. From 2001 until 2004, he chaired the Department of Gastroenterology and Hepatology at the Academic Medical Center in Amsterdam. Sander van Deventer has been a member of advisory panels of the Food and Drug Administration and the European Agency for the Evaluation of Medicinal Products. He has authored more than 80 book chapters, 350 peer review scientific papers.